Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

1期进行中（已停止招募） NCT04535401

适应症	Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
分期	1期
申办方	National Cancer Institute (NCI)
状态	进行中（已停止招募）
受试者人数	10 人
干预（药物）	Biopsy, Biospecimen Collection, Diagnostic Imaging, Elimusertib, Fluorouracil
开始日期	2021年8月13日
完成日期	2025年2月19日
结果公布日	2026年7月13日

摘要

This phase I trial investigates the best dose, possible benefits and/or side effects of BAY 1895344 in combination with FOLFIRI in treating patients with stomach or intestinal cancer that that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has spread from where it first started (primary site) to other places in the body (metastatic). BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as irinotecan, fluorouracil, and leucovorin, (called FOLFIRI in short) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BAY 1895344 in combination with FOLFIRI may help shrink advanced or metastatic stomach and/or intestinal cancer.

Maximum Tolerated Dose (MTD) of Elimusertib (BAY 1895344) in Combination With Irinotecan, Fluorouracil, and Leucovorin (FOLFIRI)

Up to 28 days · mg/m2

Elimusertib + Irinotecan + Fluorouracil + Leucovorin (FOLFIRI)	NA mg/m2

Patients Who Experienced DLTs

Up to 28 days · percentage of patients

Treatment (Elimusertib, FOLFIRI): DL-1	33.3 percentage of patients
Treatment (Elimusertib, FOLFIRI): DL-1B	66.7 percentage of patients
Treatment (Elimusertib, FOLFIRI): DL1	33.3 percentage of patients
Treatment (Elimusertib, FOLFIRI): DL1B	100 percentage of patients

在 BENITIONS 中查看查看 ClinicalTrials.gov 原文

同一适应症的其他试验

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Ad — Hoffmann-La Roche
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patient — National Cancer Institute (NCI)
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 — National Cancer Institute (NCI)
Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Un — University of Southern California
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresecta — National Cancer Institute (NCI)
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients — National Cancer Institute (NCI)

全部试验

本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。

English 한국어 日本語中文 Русский